Moderna D
D
MRNA
247.000
USD
-5.07
(-2.02%)
Pre Open·252.480USD+5.480(+2.22%)
Last updated: · Delayed 15 min
Moderna EPS (earnings per share) 2016–2026What is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
Moderna's diluted EPS in Q3 FY2026, the three months to 30 September 2026, was 0.38 USD, against a loss of 0.51 USD on the same quarter a year before. Moderna's diluted earnings per share in fiscal year 2025 were -7.26 USD, against a loss of 9.27 USD on the year before.
Last updated 6 Nov 2026 · Next report 12 Feb 2027
EPS
Growth
| Fiscal year | Period ending | EPS | Growth | EPS (basic) |
|---|---|---|---|---|
| TTM | 30 Sept 2026 | -7.09 | — | -7.07 |
| FY2025 | 31 Dec 2025 | -7.26 | — | -7.26 |
| FY2024 | 31 Dec 2024 | -9.27 | — | -9.27 |
| FY2023 | 31 Dec 2023 | -12.34 | -161.39% | -12.34 |
| FY2022 | 31 Dec 2022 | 20.10 | -28.95% | 21.26 |
| FY2021 | 31 Dec 2021 | 28.29 | — | 30.31 |
| FY2020 | 31 Dec 2020 | -1.96 | — | -1.96 |
| FY2019 | 31 Dec 2019 | -1.55 | — | -1.55 |
| FY2018 | 31 Dec 2018 | -1.17 | — | -1.17 |
| FY2017 | 31 Dec 2017 | -0.72 | — | -0.72 |
| FY2016 | 31 Dec 2016 | -3.79 | — | -3.79 |
| Quarter | Period ending | EPS | Growth on a year before | EPS (basic) |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 0.38 | — | 0.40 |
| Q2 FY2026 | 30 Jun 2026 | -1.96 | — | -1.96 |
| Q1 FY2026 | 31 Mar 2026 | -3.40 | — | -3.40 |
| Q4 FY2025 | 31 Dec 2025 | -2.11 | — | -2.11 |
| Q3 FY2025 | 30 Sept 2025 | -0.51 | -1,664.42% | -0.51 |
| Q2 FY2025 | 30 Jun 2025 | -2.13 | — | -2.13 |
| Q1 FY2025 | 31 Mar 2025 | -2.52 | — | -2.52 |
| Q4 FY2024 | 31 Dec 2024 | -2.91 | -629.09% | -2.91 |
| Q3 FY2024 | 30 Sept 2024 | 0.03 | — | 0.03 |
| Q2 FY2024 | 30 Jun 2024 | -3.33 | — | -3.33 |
| Q1 FY2024 | 31 Mar 2024 | -3.08 | -1,640.00% | -3.08 |
| Q4 FY2023 | 31 Dec 2023 | 0.55 | -84.81% | 0.57 |
| Q3 FY2023 | 30 Sept 2023 | -9.53 | -476.68% | -9.53 |
| Q2 FY2023 | 30 Jun 2023 | -3.62 | -169.08% | -3.62 |
| Q1 FY2023 | 31 Mar 2023 | 0.20 | -97.67% | 0.20 |
| Q4 FY2022 | 31 Dec 2022 | 3.62 | -67.94% | 3.81 |
| Q3 FY2022 | 30 Sept 2022 | 2.53 | -67.14% | 2.67 |
| Q2 FY2022 | 30 Jun 2022 | 5.24 | -18.89% | 5.55 |
| Q1 FY2022 | 31 Mar 2022 | 8.58 | +202.11% | 9.09 |
| Q4 FY2021 | 31 Dec 2021 | 11.29 | — | 12.03 |
| Q3 FY2021 | 30 Sept 2021 | 7.70 | — | 8.27 |
| Q2 FY2021 | 30 Jun 2021 | 6.46 | — | 6.93 |
| Q1 FY2021 | 31 Mar 2021 | 2.84 | — | 3.05 |
| Q4 FY2020 | 31 Dec 2020 | -0.69 | — | -0.69 |
| Q3 FY2020 | 30 Sept 2020 | -0.59 | — | -0.59 |
| Q2 FY2020 | 30 Jun 2020 | -0.31 | — | -0.31 |
| Q1 FY2020 | 31 Mar 2020 | -0.35 | — | -0.35 |
| Q4 FY2019 | 31 Dec 2019 | -0.37 | — | -0.37 |
| Q3 FY2019 | 30 Sept 2019 | -0.37 | — | -0.37 |
| Q2 FY2019 | 30 Jun 2019 | -0.41 | — | -0.41 |
| Q1 FY2019 | 31 Mar 2019 | -0.40 | — | -0.40 |
| Q4 FY2018 | 31 Dec 2018 | -0.44 | — | -0.44 |
| Q3 FY2018 | 30 Sept 2018 | -0.27 | — | -0.27 |
| Q2 FY2018 | 30 Jun 2018 | -0.24 | — | -0.24 |
| Q1 FY2018 | 31 Mar 2018 | -0.19 | — | -0.19 |
| Q4 FY2017 | 31 Dec 2017 | -0.13 | — | -0.13 |
| Q3 FY2017 | 30 Sept 2017 | -1.05 | — | -1.05 |
| Q2 FY2017 | 30 Jun 2017 | -1.25 | — | -1.25 |
| Q1 FY2017 | 31 Mar 2017 | -1.25 | — | -1.25 |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,Net income,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement
Common questions about Moderna's EPS
Source: Financial Modeling Prep